Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of “A-Drug”, AD-D prevention to Avert AD

Author(s): Debomoy K. Lahiri

Journal Name: Current Alzheimer Research

Volume 16 , Issue 4 , 2019

Become EABM
Become Reviewer
Call for Editor

Hsu D, Marshall GA. Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward. Curr Alzheimer Res 14(4): 426-40. (2017).
Maloney B, Lahiri DK. Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol 15(7): 760-74. (2016).
Weinstein G, Preis SR, Beiser AS, Kaess B, Chen TC, Satizabal C, et al. Clinical and environmental correlates of serum BDNF: A descriptive study with plausible implications for AD research. Curr Alzheimer Res 14(7): 722-30. (2017).
Lauritzen I, Pardossi-Piquard R, Bourgeois A, Bécot A, Checler F. Does intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s disease? Curr Alzheimer Res (2019).

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 24 April, 2019
Page: [279 - 280]
Pages: 2
DOI: 10.2174/156720501604190424114752

Article Metrics

PDF: 35
PRC: 1